Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) EBIT Margin (2019 - 2025)

Revolution Medicines has reported EBIT Margin over the past 6 years, most recently at 4757.46% for Q4 2025.

  • Quarterly results put EBIT Margin at 4757.46% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 28623.25% (changed N/A YoY), and the annual figure for FY2023 was 4207.12%, down 347711.0%.
  • EBIT Margin for Q4 2025 was 4757.46% at Revolution Medicines, up from 2758.74% in the prior quarter.
  • Over the last five years, EBIT Margin for RVMD hit a ceiling of 4757.46% in Q4 2025 and a floor of 24256.47% in Q4 2023.
  • Median EBIT Margin over the past 4 years was 681.1% (2022), compared with a mean of 2388.83%.
  • Biggest five-year swings in EBIT Margin: surged 254813bps in 2022 and later tumbled -2385394bps in 2023.
  • Revolution Medicines' EBIT Margin stood at 559.33% in 2021, then rose by 28bps to 402.52% in 2022, then crashed by -5926bps to 24256.47% in 2023, then soared by 120bps to 4757.46% in 2025.
  • The last three reported values for EBIT Margin were 4757.46% (Q4 2025), 2758.74% (Q3 2025), and 24256.47% (Q4 2023) per Business Quant data.